TRIAL DETAIL
A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. |
|||
NCT#: |
||||
Conditions: |
Breast Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Gastrointestinal Stromal Tumors |
|||
Status: |
Completed |
|||
Phase: |
3 |
Start Date 07/01/2007 |
Age of Trial (yrs) 17.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
A6181114 |
|||
Sponsor: |
Pfizer |
|||
Patient Contact: |
Pfizer Oncology Clinical Trial Information Service |
|||
Contact email: |
PfizerCancerTrials@emergingmed.com |
|||
Contact Phone: |
1-877-369-9753 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181107, A6181108, A6181110, A6181111, or A6181112. At last check 10/05/2011 one site was still recruiting in Taiwan. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |